The study, therefore, sheds light on the mechanisms underlying the renoprotective capacity of NAD+ and identifies NAD+/SIRT1/GSK‐3β/Nrf2 pathway as a potential therapeutic target, which might be used to prevent or ameliorate sepsis‐induced AKI. The gene discussed is SIRT1; the disease is acute kidney injury.